[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase-1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model

What is the purpose of the study? (in Layman's terms, please describe the study)

To test the effectiveness of an oral drug candidate against dengue virus. This virus causes Dengue fever, a problematic disease for much of the developing world and also for deployed military personnel.

Upstate Institutional Review Board (IRB) Number:

1846237

Study/Protocol ID:

AT-02A-003

Study Phase:

1

Patient Age Group:

Adults

Principal Investigator:

Stephen J Thomas

Who is eligible?

Healthy adults ages 18-49

What is involved if I participate?

  • How long is the study?
    4 months. Visits are frequent during the first two weeks.
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Blood draws for labs, physical assessment, ECG, challenge with dengue virus

Where will the study take place?

Global Health Research Unit, Upstate Community campus (4900 Broad Road, Syracuse), POB-North Suite 4U

Other Information:

Students are especially welcome, but any healthy adult with a flexible schedule and a desire to advance the science of treating dengue fever is welcome to make an appointment for screening.

Who can I contact for more information?

Name: Michelle D Klick
Phone: 315-464-5729
Email: [email protected]

Return to Previous Page || Search Again

Top